CR11762A - Uso del factor liberador de corticotropina para el tratamiento de cancer - Google Patents
Uso del factor liberador de corticotropina para el tratamiento de cancerInfo
- Publication number
- CR11762A CR11762A CR11762A CR11762A CR11762A CR 11762 A CR11762 A CR 11762A CR 11762 A CR11762 A CR 11762A CR 11762 A CR11762 A CR 11762A CR 11762 A CR11762 A CR 11762A
- Authority
- CR
- Costa Rica
- Prior art keywords
- release factor
- cancer treatment
- corticotropine
- corticotropine release
- factor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se determina en la presente un método para tratar cáncer en un ser humano administrando una alta dosis del factor de liberación de corticotropina (CRF) durante un periodo de tiempo que excede 3 días
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4929208P | 2008-04-30 | 2008-04-30 | |
US9480608P | 2008-09-05 | 2008-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR11762A true CR11762A (es) | 2011-04-26 |
Family
ID=41119761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR11762A CR11762A (es) | 2008-04-30 | 2010-10-27 | Uso del factor liberador de corticotropina para el tratamiento de cancer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20100113341A1 (es) |
EP (1) | EP2259793A2 (es) |
JP (1) | JP2011519375A (es) |
KR (1) | KR20110021820A (es) |
CN (1) | CN102036680A (es) |
AU (1) | AU2009241813A1 (es) |
CA (1) | CA2722426A1 (es) |
CO (1) | CO6300959A2 (es) |
CR (1) | CR11762A (es) |
EC (1) | ECSP10010631A (es) |
IL (1) | IL209005A0 (es) |
MX (1) | MX2010011882A (es) |
NI (1) | NI201000185A (es) |
NZ (1) | NZ588877A (es) |
RU (1) | RU2010148803A (es) |
WO (1) | WO2009134396A2 (es) |
ZA (1) | ZA201007729B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010057962A2 (en) * | 2008-11-19 | 2010-05-27 | Neutron Limited | Crf conjugates with extended half-lives |
BRPI1012262A2 (pt) * | 2009-06-24 | 2016-04-05 | Stephen Evans Freke | "método de uso do fator liberador de corticotropina para o tratamento de câncer" |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2852054A (en) * | 1956-11-23 | 1958-09-16 | Motley Murat Brunson | Container and closure therefor |
US4312523A (en) * | 1979-10-29 | 1982-01-26 | Paco Packaging Incorporated | Label for container having pharmaceutical product therein |
US4415558A (en) * | 1981-06-08 | 1983-11-15 | The Salk Institute For Biological Studies | CRF And analogs |
EP0120000A1 (en) * | 1982-09-29 | 1984-10-03 | LEDERIS, Karl P. | Urotensin peptides |
US4528189A (en) * | 1983-02-03 | 1985-07-09 | The Salk Institute For Biological Studies | Urotensin peptides |
US4489163A (en) * | 1983-04-14 | 1984-12-18 | The Salk Institute For Biological Studies | rCRF and analogs |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5229940A (en) * | 1992-01-29 | 1993-07-20 | Conoco Inc. | Method of extracting three dimensional information from a grid of two dimensional seismic data |
US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
US6319900B1 (en) * | 1999-09-21 | 2001-11-20 | The Regents Of The University Of California | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
CN1361180A (zh) * | 2000-12-26 | 2002-07-31 | 上海博德基因开发有限公司 | 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸 |
CN1382700A (zh) * | 2001-04-26 | 2002-12-04 | 上海博德基因开发有限公司 | 一种多肽——促肾上腺皮质激素释放因子-12.87和编码这种多肽的多核苷酸 |
CA2358177A1 (en) * | 2001-10-03 | 2003-04-03 | Ted Ramsay | Label for pharmaceutical prescriptions |
KR101160611B1 (ko) * | 2003-05-12 | 2012-06-28 | 아피맥스, 인크. | 폴리(에틸렌 글리콜)로 변형된 펩티드 기재 화합물용 신규 스페이서 부분 |
EP1761281A1 (en) * | 2004-06-04 | 2007-03-14 | Pfizer Products Incorporated | Method for treating abnormal cell growth |
AU2005276242B2 (en) * | 2004-07-08 | 2011-08-25 | Aimsco Limited | Medicament |
JP2006036013A (ja) * | 2004-07-27 | 2006-02-09 | Yamaha Motor Co Ltd | 自動二輪車 |
US7311205B2 (en) * | 2005-01-25 | 2007-12-25 | Target Brands, Inc. | Pharmacy bottle system including label |
US20100203048A1 (en) * | 2008-04-30 | 2010-08-12 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the use of the treatment of cancer |
-
2009
- 2009-04-30 WO PCT/US2009/002645 patent/WO2009134396A2/en active Application Filing
- 2009-04-30 US US12/433,652 patent/US20100113341A1/en not_active Abandoned
- 2009-04-30 CA CA2722426A patent/CA2722426A1/en not_active Abandoned
- 2009-04-30 EP EP09739199A patent/EP2259793A2/en not_active Withdrawn
- 2009-04-30 MX MX2010011882A patent/MX2010011882A/es not_active Application Discontinuation
- 2009-04-30 RU RU2010148803/15A patent/RU2010148803A/ru not_active Application Discontinuation
- 2009-04-30 NZ NZ588877A patent/NZ588877A/xx not_active IP Right Cessation
- 2009-04-30 JP JP2011507449A patent/JP2011519375A/ja active Pending
- 2009-04-30 AU AU2009241813A patent/AU2009241813A1/en not_active Abandoned
- 2009-04-30 CN CN2009801188091A patent/CN102036680A/zh active Pending
- 2009-04-30 KR KR1020107026626A patent/KR20110021820A/ko not_active Application Discontinuation
-
2010
- 2010-10-27 CR CR11762A patent/CR11762A/es not_active Application Discontinuation
- 2010-10-28 ZA ZA2010/07729A patent/ZA201007729B/en unknown
- 2010-10-28 IL IL209005A patent/IL209005A0/en unknown
- 2010-10-28 NI NI201000185A patent/NI201000185A/es unknown
- 2010-11-23 CO CO10146559A patent/CO6300959A2/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010631A patent/ECSP10010631A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20110021820A (ko) | 2011-03-04 |
WO2009134396A2 (en) | 2009-11-05 |
US20100113341A1 (en) | 2010-05-06 |
MX2010011882A (es) | 2011-02-25 |
CO6300959A2 (es) | 2011-07-21 |
CA2722426A1 (en) | 2009-11-05 |
RU2010148803A (ru) | 2012-06-10 |
ZA201007729B (en) | 2014-02-26 |
NI201000185A (es) | 2013-04-22 |
JP2011519375A (ja) | 2011-07-07 |
WO2009134396A3 (en) | 2010-04-15 |
ECSP10010631A (es) | 2011-02-28 |
IL209005A0 (en) | 2011-01-31 |
AU2009241813A1 (en) | 2009-11-05 |
NZ588877A (en) | 2012-08-31 |
EP2259793A2 (en) | 2010-12-15 |
CN102036680A (zh) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
MX2020009773A (es) | Terapia de combinacion. | |
EA201100335A1 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
CL2011000099A1 (es) | Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria. | |
CO6450651A2 (es) | Terapia complementaria contra el cancer | |
CY1125948T1 (el) | Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου | |
CY1110341T1 (el) | Παραγωγα κιναζολινης και η χρηση τους στην θεραπευτικη αγωγη θρομβοκυτταραιμιας | |
CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
MX2019003134A (es) | Terapia de combinacion. | |
MX2020001727A (es) | Terapia de combinacion. | |
AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
UY33740A (es) | Método para tratar el cáncer de mama y cáncer de ovarios | |
DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
DK1965801T3 (da) | Kombination af azd2171 og pemetrexed | |
CR11762A (es) | Uso del factor liberador de corticotropina para el tratamiento de cancer | |
CR20110687A (es) | Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer | |
AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
AR047154A1 (es) | Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol | |
AR073585A1 (es) | Una proteina rica en cisteina derivada de suero en pacientes que reciben quimioterapia o radioterapia para mejorar la supervivencia de dichos pacientes. uso. metodo | |
ATE540920T1 (de) | Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie | |
MX2021001764A (es) | Terapia de combinacion. | |
EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |